We follow industry news and trends so you can stay ahead of the game. Subscribe to receive emails regarding policies and findings that impact you and your business.

Already a subscriber and want to update your preferences? Click here.

BACK TO NEWS

MEDIA MENTIONS

OCT 18 2018

Breaking Down HHS Drug Advertisement, Price Transparency Proposal - Patient Engagement HIT

Will Garvin, shareholder in the firm's FDA & Biotechnology practice, provides detailed commentary on the Trump Administration's latest effort to address all-time-high out-of-pocket drug costs, possible effects of a newly proposed rule for price transparency in advertisements and the debate between pharmaceutical companies and the Department of Health and Human Services in Patient Engagement HIT's "Breaking Down HHS Drug Advertisement, Price Transparency Proposal."